These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000607-17 A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma bad-data
Reported results 2007-002917-38 A Randomised, Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-... 2011-05-05 due-trials
Reported results 2007-004761-17 A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previousl... 2010-09-14 due-trials
Reported results 2008-006034-10 A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL) 2015-05-14 due-trials
Reported results 2008-006035-12 A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) 2016-06-06 due-trials
Reported results 2009-016947-20 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual... 2020-05-06 due-trials
Reported results 2010-019932-11 Treatment with SGN-35 in patients with CD30-positive hematologic malignancies who have previously participated in an SGN-35 study 2013-03-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-020363-21 An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma 2020-08-21 bad-data
Reported results 2012-002751-42 A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas 2020-10-02 due-trials
Reported results 2015-001671-51 A RANDOMIZED, OPEN LABEL, PHASE 2 STUDY OF RITUXIMAB AND BENDAMUSTINE WITH OR WITHOUT BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY CD30-POSITIVE DIFFUSE LARGE B CELL LYMPHOMA 2017-09-30 due-trials
Listed as ongoing, but also has a completion date 2015-002801-12 Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic H... 2022-08-11 bad-data
Reported results 2015-003482-28 A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute... 2017-10-03 due-trials
Reported results 2015-004741-54 A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosphami... 2017-05-01 due-trials
Exempt 2017-002289-35 Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Canc... not-yet-due
Listed as ongoing, but also has a completion date 2017-003479-78 A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i... 2020-04-06 bad-data
Other 2017-005076-26 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors not-yet-due
Listed as ongoing, but also has a completion date 2019-001219-22 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen 2022-02-08 bad-data
Other 2019-001946-17 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors not-yet-due
Completed, but no date, and reported results Terminated 2019-003982-17 A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant co... bad-data
Ongoing 2019-004542-15 An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial ... not-yet-due
Ongoing 2019-005017-39 Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer ... not-yet-due
Ongoing 2020-000540-60 MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer not-yet-due
Ongoing 2020-002336-74 A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression Étu... not-yet-due
Ongoing 2020-002686-33 A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed... not-yet-due